VKTX · XBRL financial data

Viking Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VKTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	0	0	0	0	0
Research and development	31,931	44,981	54,234	63,806	101,644	344,955
General and administrative	10,731	10,701	16,121	37,021	49,277	48,387
Total operating expenses	42,662	55,682	70,355	100,827	150,921	393,342
Operating income (loss)	(42,662)	(55,682)	(70,355)	(100,827)	(150,921)	(393,342)
Other income (expense)	3,167	692	1,488	14,932	40,958	33,703
Income tax expense (benefit)	0	2	1	1	1	1
Net income (loss)	(39,495)	(54,990)	(68,867)	(85,895)	(109,963)	(359,639)
Earnings per share, basic USD per share	—	(0.71)	(0.90)	(0.91)	(1.01)	(3.19)
Earnings per share, diluted USD per share	—	(0.71)	(0.90)	(0.91)	(1.01)	(3.19)
Weighted average shares, basic thousands of shares	—	77,198	76,834	94,347	109,037	112,667
Weighted average shares, diluted thousands of shares	—	77,198	76,834	94,347	109,037	112,667

Fiscal years (VKTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	29,117	26,371	36,632	55,516	26,676	165,810
Marketable securities	219,269	175,732	118,853	306,563	875,936	539,929
Prepaid and other current assets	442	619	3,411	2,522	1,128	1,806
Total current assets	256,104	210,528	167,040	367,225	907,216	715,598
Right-of-use asset	321	25	1,418	1,126	1,003	85
Total assets	256,502	210,662	168,529	368,490	908,321	715,729
Accounts payable	3,988	1,444	8,529	7,512	9,813	53,251
Total current liabilities	12,129	8,778	21,947	19,135	27,413	76,667
Lease liability, non-current	29	—	1,260	936	630	0
Total liabilities	12,158	8,778	23,207	20,071	28,043	76,667
Accumulated deficit	(168,192)	(223,182)	(292,049)	(377,944)	(487,907)	(847,546)
Total stockholders' equity	244,344	201,884	145,322	348,419	880,278	639,062
Total liabilities and equity	256,502	210,662	168,529	368,490	908,321	715,729
Common shares outstanding (cover page) thousands of shares	74,133	78,363	78,419	100,488	112,248	115,554

Fiscal years (VKTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(39,495)	(54,990)	(68,867)	(85,895)	(109,963)	(359,639)
Stock-based compensation	5,818	6,100	8,673	16,750	29,712	40,818
Net cash from operating activities	(21,777)	(47,586)	(48,397)	(73,376)	(87,790)	(278,685)
Net cash from investing activities	41,567	37,960	54,753	(179,086)	(553,366)	341,388
Share repurchases	—	—	6,795	—	—	—
Net cash from financing activities	950	6,880	4,163	271,376	612,464	76,439
Net change in cash	20,740	(2,746)	10,519	—	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Viking Therapeutics	677,609	0	(138,194)*	127.5M	7.6 quarters	Q3 FY26 10-QSep 30, 2026
Prestige Consumer Healthcare	89,127	265,710	70,788	47.4M	—	Q1 FY27 10-QJun 30, 2026
Protagonist Therapeutics	420,078	213,475	219,052*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Ultragenyx Pharmaceutical	125,000	214,000	(97,000)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	382,517	860*	(169,773)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Catalyst Pharmaceuticals	755,859	149,390	59,587	122.4M	—	Q1 FY26 10-QMar 31, 2026
Cytokinetics	255,271	28,624	(159,840)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	482,575	240,335	39,263*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	419,365	not reported	(141,124)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.